AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10599905
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no doxycycline administration)
Trial: 28463040
Drug: UD‐DPI (400 μg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UD‐DPI (400 μg, 0.8% lactose blend)
Trial: 17251482
Drug: Pentoxifylline (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (300 mg)
Trial: 14698543
Drug: Vinorelbine (V)
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine (V) 25mg/m2 IV infusion + Gemcitabine (G) 1000 mg/m2 IV infusion on days 1 and 8 of each 21-day cycle
Trial: 11008329
Drug: Captopril (25-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25-75 mg/day)
Trial: 9562938
Drug: Fosinopril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (10-20 mg/day)
Trial: 30870225
Drug: Adjuvant capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adjuvant capecitabine monotherapy for 8 cycles
Trial: 28438924
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (rifampin and isoniazid for 6 months; pyrazinamide and ethambutol for 2 months)
Trial: 22013794
Drug: Lipid-reducing red
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-reducing red rice minute powder (LRRMP) 175 mg/pill, 2 pills daily for 6 months
Trial: 19079839
Drug: High-soya diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-soya diet (two daily servings with 3035mg isoflavones per serving)
Trial: 22079088
Drug: Sitaxsentan 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitaxsentan 100 mg
Trial: 22079088
Drug: Sitaxsentan 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitaxsentan 50 mg
Trial: 11306776
Drug: Heparin (activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (activated partial thromboplastin time 2‐3 times of baseline value)
Trial: 7524296
Drug: Amiodarone 100
RxNorm normalized name: amiodarone 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone 100 mg/day
Trial: 2655611
Drug: Cicletanine 50
RxNorm normalized name: cicletanine 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicletanine 50 mg/d
Trial: 2655611
Drug: Cicletanine 100
RxNorm normalized name: cicletanine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cicletanine 100 mg/d
Trial: 239414
Drug: Ephedrine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (25 mg)
Trial: 10589631
Drug: Ropivacaine 5
RxNorm normalized name: fentanyl-ropivacaine 5 mcg/mL-0.1%-0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 5 mg/mL
Trial: 15635515
Drug: Bupivacaine 5
RxNorm normalized name: Sure-Amp BUPivacaine 5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 5 mg/mL
Trial: 30760332
Drug: Negative pressure
RxNorm normalized name: DRESSING,NEGATIVE PRESSURE WOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative pressure wound therapy (NPWT) with silver-impregnated dressings via RENASYS TOUCH vacuum pump
Trial: 30760332
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy consisting of Acticoat TM and Mepitel TM
Trial: 17504895
Drug: Baseline bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline bone age delay, target height SDS, baseline height SDS, and GH dose
Trial: 15354005
Drug: Scopolamine 0.4
RxNorm normalized name: scopolamine 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine 0.4 mg
Trial: 15354005
Drug: Meclizine 25
RxNorm normalized name: meclizine 25 MG
DrugBank: Meclizine (DB00737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meclizine 25 mg
Trial: 9678531
Drug: Evening s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening s.c. GH injections (2 IU)
Trial: 9678531
Drug: Morning s.c.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning s.c. GH injections (2 IU)
Trial: 2294131
Drug: No GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No GH administration
Trial: 9678531
Drug: Continuous i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous i.v. infusion of GH (2000-2000 h)
Trial: 5565516
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (stopped or changed)
Trial: 5565516
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (remained on the same)
Trial: 11140558
Drug: SRP+gel
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP+gel
Trial: 12490770
Drug: Moclobemide (300-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (300-600 mg/day)
Trial: 3897082
Drug: Ephedrine 50
RxNorm normalized name: Ephedrine 50 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine 50 mg t.i.d.
Trial: 29895502
Drug: Live-attenuated Suvaxyn®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live-attenuated Suvaxyn® CSF Marker vaccine (CP7_E2alf), administered intramuscularly on day 44 of gestation.
Trial: 19830558
Drug: Probiotics (Bacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Bacillus subtilis and Streptococcus faecium) for 2 weeks with oral sodium phosphate (NaP)
Trial: 19830558
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with oral sodium phosphate (NaP)
Trial: 8708713
Drug: Ondansetron 32
RxNorm normalized name: ondansetron 32 MG in 50 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 32 mg
Trial: 16766588
Drug: Palonosetron 0.25
RxNorm normalized name: palonosetron 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 0.25 mg with dexamethasone
Trial: 12869893
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 13-15 mg/kg/d
Trial: 31599168
Drug: Group counselling
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group counselling (4 weekly sessions)
Trial: 31520480
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment with porous tantalum rod implantation and intra-arterial infusion of peripheral blood stem cells (PBSCs)
Trial: 16790655
Drug: Intravenous small-dose
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous small-dose morphine (4 mg/70 kg)
Trial: 9734695
Drug: Low-dose cytarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytarabine (LoDAC)
Trial: 2550700
Drug: CMV‐HIGP (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMV‐HIGP (1 ml per kilogram of body weight) every two to three weeks initially, with double dose for basic immunisation protection
Trial: 22253279
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml of glucose syrup 15%
Trial: 16309081
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (all methods combined)
Trial: 27127
Drug: 0.4 mg
RxNorm normalized name: biotin 0.4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg Pindolol (Visken)
Trial: 25514804
Drug: Afatinib (≤50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (≤50 mg daily, monotherapy)
Trial: 23616386
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with Dermatophagoides pteronyssinus (D.p.) and Dermatophagoides farina (D.f.) extract (n = 60)
Trial: 22038349
Drug: Doxofylline oral
RxNorm normalized name: doxofylline
DrugBank: Doxofylline (DB09273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxofylline oral tablets (0.2 g/time, 2 times a day)
Trial: 26211516
Drug: Shakuyakukanzoto (SKT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shakuyakukanzoto (SKT) 2.5 g/day
Trial: 20100811
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg alagebrium twice daily
Trial: 10744202
Drug: Topical dorzolamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dorzolamide 2% (Trusopt) three times daily for three days
Trial: 10744202
Drug: Oral acetozolamide
RxNorm normalized name: acetazolamide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetozolamide (Diazomide) 250 mg three times daily for three days
Trial: 8774390
Drug: Intermittent intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intravenous 1 alpha(OH)D3 treatment for > 300 days
Trial: 8774390
Drug: Intermittent oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent oral 1 alpha(OH)D3 treatment for 100 days
Trial: 8774390
Drug: Reinstatement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reinstatement of intermittent intravenous 1 alpha(OH)D3 treatment for another 100 days
Trial: 1727741
Drug: Captopril 25
RxNorm normalized name: captopril 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 25 mg (b.i.d.)
Trial: 6653133
Drug: Paracetamol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (500 mg) plus metoclopramide (5 mg)
Trial: 6653133
Drug: Paracetamol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (500 mg) alone
Trial: 2544829
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous methylprednisolone
Trial: 26350667
Drug: Subcutaneous enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous enoxaparin 30 mg b.i.d.
Trial: 23870610
Drug: Intravenous midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous midazolam (2.5 mg) after ticagrelor (270 mg single dose, then 180 mg BID for 6 days)
Trial: 19775041
Drug: Lactated solution
RxNorm normalized name: lactate Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactated solution (Hartmann's solution; anions: chloride 109 mmol/l, lactate 29 mmol/l)
Trial: 19775041
Drug: Chloride-only solution
RxNorm normalized name: CHLORIDE
DrugBank: Chloride ion (DB14547)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloride-only solution (Ringer's Injection; anions: chloride 152 mmol/l)
Trial: 8163252
Drug: Pravastatin 20
RxNorm normalized name: pravastatin 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 20 mg once daily at bedtime
Trial: 28749571
Drug: Intravenous L-ornithine
RxNorm normalized name: L-Ornithine
DrugBank: Ornithine (DB00129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous L-ornithine L-aspartate (LOLA), 30g daily for 5 days
Trial: 25803546
Drug: Control capsules
RxNorm normalized name: Azo Men Bladder Control Capsules(obs)
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control capsules
Trial: 23593611
Drug: peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peginterferon alfa-2a plus ribavirin therapy (Clinical Trial group)
Trial: 23593611
Drug: peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: peginterferon alfa-2a plus ribavirin therapy (Cohort group)
Trial: 19932589
Drug: ProMECE-CytaBOM infusion
RxNorm normalized name: PROMACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ProMECE-CytaBOM infusion
Trial: 12520631
Drug: Nizatidine CR
RxNorm normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nizatidine CR 150 mg bid
Trial: 12520631
Drug: Nizatidine CR
RxNorm normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nizatidine CR 300 mg daily
Trial: 7934692
Drug: Preoperative iliohypogastric
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative iliohypogastric ilioinguinal nerve block (IINB) with 0.25% bupivacaine at 1 mg/Kg
Trial: 7934692
Drug: Postoperative iliohypogastric
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative iliohypogastric ilioinguinal nerve block (IINB) with 0.25% bupivacaine at 1 mg/Kg
Trial: 20146569
Drug: Rotterdam Empirical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotterdam Empirical Steering Guidelines (RESG) during the second and third treatments
Trial: 20146569
Drug: Hyperthermia treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermia treatment planning guided steering (HGS) during the fourth and fifth treatments
Trial: 20146569
Drug: Rotterdam Empirical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotterdam Empirical Steering Guidelines (RESG) during the fourth and fifth treatments
Trial: 25809790
Drug: Couple-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couple-based treatment with emphasis on 'we' language
Trial: 25809790
Drug: Couple-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Couple-based treatment with emphasis on 'you' and 'I' language
Trial: 22080174
Drug: 7.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 μg H5N1 haemagglutinin antigen
Trial: 22080174
Drug: Cross-reactive antibody
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross-reactive antibody response
Trial: 22080174
Drug: Persistence of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persistence of antibodies
Trial: 22080174
Drug: Safety of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety of the vaccine
Trial: 16136769
Drug: Fluticasone propionate-salmeterol
RxNorm normalized name: Fluticasone Propionate/Salmeterol Xinafoate 55 MCG/1 ACTUATION-14 MCG/1 ACTUATION Inhalation Powder [FLUTICASONE PROPIONATE-SALMETEROL XINAFOATE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate-salmeterol (100/50 microg, twice daily)
Trial: 16136769
Drug: Montelukast (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (once daily)
Trial: 12351465
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (4 g daily for 8 weeks)
Trial: 30387859
Drug: Chewed Oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chewed Oxycodone DETERx fasted
Trial: 30387859
Drug: Intact Oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact Oxycodone DETERx fasted
Trial: 30387859
Drug: Intact Oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact Oxycodone DETERx fed
Trial: 21309477
Drug: Semi-closed circuit
RxNorm normalized name: Semi-Daonil
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semi-closed circuit anaesthesia (SCA) 4 l/min
Trial: 16244028
Drug: Alkalinized lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alkalinized lidocaine with 1.4% NaHCO3 (group small dose)
Trial: 7607749
Drug: Other treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other treatments (including sucrose gum)
Trial: 2230911
Drug: Ceftriaxone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2 g i.v.) at the time of anesthesia
Trial: 31702486
Drug: Cilostazol 100
RxNorm normalized name: cilostazol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol 100 mg twice daily for 4 days followed by metoclopramide 20 mg
Trial: 26237354
Drug: Inhaled Interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Interferon gamma (IFN‐γ) for 80 weeks
Trial: 31119846
Drug: TRK‐100STP 240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRK‐100STP 240 μg
Trial: 17115157
Drug: AZD5438 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5438 80 mg
Trial: 17115157
Drug: AZD5438 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5438 160 mg
Trial: 17115157
Drug: AZD5438 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5438 (various doses)
Trial: 8094111
Drug: Active taper
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active taper
Trial: 29247782
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with 1000 IU of vitamin D and 500 mg of calcium for six months
Trial: 29247782
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with 1000 IU of vitamin D and 500 mg of calcium
Trial: 26712558
Drug: Aminophylline (theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (theophylline salt formulation)
Trial: 10208192
Drug: Inhaled salmeterol
RxNorm normalized name: salmeterol Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled salmeterol (42 microg twice daily)
Trial: 10208192
Drug: Inhaled ipratropium
RxNorm normalized name: ipratropium Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled ipratropium bromide (36 microg four times a day)
Trial: 10208192
Drug: Inhaled placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled placebo (2 puffs four times a day)
Trial: 7788426
Drug: Oral atovaquone
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral atovaquone for mild to moderate PCP
Trial: 7788426
Drug: Oral atovaquone
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral atovaquone for severe PCP
Trial: 9742976
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (overall)
Trial: 8048498
Drug: Dexamethasone (Dex)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (Dex) + Spironolactone (Spi) (200 mg)
Trial: 8048498
Drug: Dexamethasone (Dex)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (Dex) + Mifepristone (Mif) (400 mg)
Trial: 1101838
Drug: Spironolactone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (300 to 450 mg daily)
Trial: 19837005
Drug: Spinal Manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal Manipulative Therapy (SMT)
Trial: 21300181
Drug: Replication‐Competent Adenovirus‐mediated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Replication‐Competent Adenovirus‐mediated Suicide Gene Therapy followed by radiation (Arm 1)
Trial: 17886708
Drug: Concomitant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemotherapy and radiotherapy
Trial: 2440632
Drug: Propafenone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (300 mg three times a day)
Trial: 29127949
Drug: Ranibizumab plus
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab plus intravitreous dexamethasone implant (700 μg)
Trial: 29127949
Drug: Ranibizumab (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranibizumab (0.3 mg) alone
Trial: 26091907
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (methotrexate+golimumab)
Trial: 24168956
Drug: Methotrexate-monotherapy
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate-monotherapy
Trial: 25172879
Drug: Text messaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text messaging intervention (daily motivational messages about nutrition and physical activity)
Trial: 10447578
Drug: Nolatrexed 725
RxNorm normalized name: Nolatrexed
DrugBank: Nolatrexed (DB12912)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nolatrexed 725 mg/m(2)/day by continuous infusion for 5 days
Trial: 10447578
Drug: Doxorubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m(2) as rapid intravenous infusion every 3 weeks
Trial: 7783102
Drug: Insulin infusion
RxNorm normalized name: iLet Insulin Infusion 10-Pack Kit Inset
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin infusion (7.1 pM/kg per min) during euglycemic hyperinsulinaemic glucose clamp
Trial: 7783102
Drug: Fasting plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasting plasma insulin concentrations
Trial: 569995
Drug: Domperidone 10
RxNorm normalized name: domperidone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 10 mg IV